THE ROLE OF FRICTIONAL STRENGTH

[1] At a subduction zone the amount of friction between the incoming plate and the forearc is an important factor in controlling the dip angle of subduction and the structure of the forearc. In this paper, we investigate the role of the frictional strength of sediments and of the serpentinized peridotite on the evolution of convergent margins. In numerical models, we vary thickness of a serpentinized layer in the mantle wedge (15 to 25 km) and the frictional strength of both the sediments and serpentinized mantle (friction angle 1° to 15°, or static friction coefficient 0.017 to 0.27) to control the amount of frictional coupling between the plates. With plastic strain weakening in the lithosphere, our numerical models can attain stable subduction geometry over millions of years. We find that the frictional strength of the sediments and serpentinized peridotite exerts the largest control on the dip angle of the subduction interface at seismogenic depths. In the case of low sediment and serpentinite friction, the subduction interface has a shallow dip, while the subduction zone develops an accretionary prism, a broad forearc high, a deep forearc basin, and a shallow trench. In the high friction case, the subduction interface is steep, the trench is deeper, and the accretionary prism, forearc high and basin are all absent. The resultant free-air gravity and topographic signature of these subduction zone models are consistent with observations. We believe that the low-friction model produces a geometry and forearc structure similar to that of accretionary margins. Conversely, models with high friction angles in sediments and serpentinite develop characteristics of an erosional convergent margin. We find that the strength of the subduction interface is critical in controlling the amount of coupling at the seismogenic zone and perhaps ultimately the size of the largest earthquakes at subduction zones

Halo White Dwarfs and the Hot Intergalactic Medium

We present a schematic model for the formation of baryonic galactic halos and hot gas in the Local Group and the intergalactic medium. We follow the dynamics, chemical evolution, heat flow and gas flows of a hierarchy of scales, including: protogalactic clouds, galactic halos, and the Local Group itself. Within this hierarchy, the Galaxy is built via mergers of protogalactic fragments. We find that early bursts of star formation lead to a large population of remnants (mostly white dwarfs), which would reside presently in the halo and contribute to the dark component observed in the microlensing experiments. The hot, metal-rich gas from early starbursts and merging evaporates from the clouds and is eventually incorporated into the intergalactic medium. The model thus suggests that most microlensing objects could be white dwarfs (m \sim 0.5 \msol), which comprise a significant fraction of the halo mass. Furthermore, the Local Group could have a component of metal-rich hot gas similar to, although less than, that observed in larger clusters. We discuss the known constraints on such a scenario and show that all local observations can be satisfied with present data in this model. The best-fit model has a halo that is 40% baryonic, with an upper limit of 77%.Comment: 15 pages, LaTex, uses aas2pp4.sty, 7 postscript figures. Substantially revised and enlarged to a full-length article. Somewhat different quantitative results, but qualitative conclusions unchange

Solar-type dynamo behaviour in fully convective stars without a tachocline

In solar-type stars (with radiative cores and convective envelopes), the magnetic field powers star spots, flares and other solar phenomena, as well as chromospheric and coronal emission at ultraviolet to X-ray wavelengths. The dynamo responsible for generating the field depends on the shearing of internal magnetic fields by differential rotation. The shearing has long been thought to take place in a boundary layer known as the tachocline between the radiative core and the convective envelope. Fully convective stars do not have a tachocline and their dynamo mechanism is expected to be very different, although its exact form and physical dependencies are not known. Here we report observations of four fully convective stars whose X-ray emission correlates with their rotation periods in the same way as in Sun-like stars. As the X-ray activity - rotation relationship is a well-established proxy for the behaviour of the magnetic dynamo, these results imply that fully convective stars also operate a solar-type dynamo. The lack of a tachocline in fully convective stars therefore suggests that this is not a critical ingredient in the solar dynamo and supports models in which the dynamo originates throughout the convection zone.Comment: 6 pages, 1 figure. Accepted for publication in Nature (28 July 2016). Author's version, including Method

Landuse and soil degradation in the southern Maya lowlands, from Pre-Classic to Post-Classic times : The case of La Joyanca (Petén, Guatemala)

International audienceThis work focuses on the impact of Maya agriculture on soil degradation. In site and out site studies in the area of the city of La Joyanca (NW Petén) show that "Maya clays" do not constitute a homogeneous unit, but represent a complex sedimentary record. A high resolution analysis leads us to document changes in rates and practices evolving in time in relation with major socio-political and economic changes. It is possible to highlight extensive agricultural practices between Early Pre-classical to Late Pre-classical times. Intensification occurs in relation with reduction of the fallow duration during Pre-classic to Classic periods. The consequences of these changes on soil erosion are discussed. However, it does not seem that the agronomic potential of the soils was significantly degraded before the end of the Classic period

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

PURPOSE: Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). METHODS: ARCHES (ClinicalTrials.gov identifier: NCT02677896) is a multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to enzalutamide (160 mg/day) or placebo, plus androgen deprivation therapy (ADT), stratified by disease volume and prior docetaxel chemotherapy. The primary end point was radiographic progression-free survival. RESULTS: As of October 14, 2018, the risk of radiographic progression or death was significantly reduced with enzalutamide plus ADT versus placebo plus ADT (hazard ratio, 0.39; 95% CI, 0.30 to 0.50; P < .001; median not reached v 19.0 months). Similar significant improvements in radiographic progression-free survival were reported in prespecified subgroups on the basis of disease volume and prior docetaxel therapy. Enzalutamide plus ADT significantly reduced the risk of prostate-specific antigen progression, initiation of new antineoplastic therapy, first symptomatic skeletal event, castration resistance, and reduced risk of pain progression. More men achieved an undetectable prostate-specific antigen level and/or an objective response with enzalutamide plus ADT (P < .001). Patients in both treatment groups reported a high baseline level of quality of life, which was maintained over time. Grade 3 or greater adverse events were reported in 24.3% of patients who received enzalutamide plus ADT versus 25.6% of patients who received placebo plus ADT, with no unexpected adverse events. CONCLUSION: Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamide in previous clinical trials in castration-resistant prostate cancer

MRI-targeted or standard biopsy for prostate-cancer diagnosis

Background Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited. Methods In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostate cancer; men whose MRI results were not suggestive of prostate cancer were not offered biopsy. Standard biopsy was a 10-to-12-core, transrectal ultrasonography-guided biopsy. The primary outcome was the proportion of men who received a diagnosis of clinically significant cancer. Secondary outcomes included the proportion of men who received a diagnosis of clinically insignificant cancer. Results A total of 500 men underwent randomization. In the MRI-targeted biopsy group, 71 of 252 men (28%) had MRI results that were not suggestive of prostate cancer, so they did not undergo biopsy. Clinically significant cancer was detected in 95 men (38%) in the MRI-targeted biopsy group, as compared with 64 of 248 (26%) in the standard-biopsy group (adjusted difference, 12 percentage points; 95% confidence interval [CI], 4 to 20; P=0.005). MRI, with or without targeted biopsy, was noninferior to standard biopsy, and the 95% confidence interval indicated the superiority of this strategy over standard biopsy. Fewer men in the MRI-targeted biopsy group than in the standard-biopsy group received a diagnosis of clinically insignificant cancer (adjusted difference, -13 percentage points; 95% CI, -19 to -7; P&lt;0.001). Conclusions The use of risk assessment with MRI before biopsy and MRI-targeted biopsy was superior to standard transrectal ultrasonography-guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously. (Funded by the National Institute for Health Research and the European Association of Urology Research Foundation; PRECISION ClinicalTrials.gov number, NCT02380027 .)

Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death:Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer

Background: The European Association of Urology guidelines recommend a risk-based strategy for prostate cancer screening based on the first prostate-specific antigen (PSA) level and age. Objective: To analyze the impact of the first PSA level on prostate cancer (PCa) detection and PCa-specific mortality (PCSM) in a population-based screening trial (repeat screening every 2–4 yr). Design, setting, and participants: We evaluated 25 589 men aged 55–59 yr, 16 898 men aged 60–64 yr, and 12 936 men aged 65–69 yr who attended at least one screening visit in the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial (screening arm: repeat PSA testing every 2–4 yr and biopsy in cases with elevated PSA; control arm: no active screening offered) during 16-yr follow-up (FU). Outcome measurements and statistical analysis: We assessed the actuarial probability for any PCa and for clinically significant (cs)PCa (Gleason ≥7). Cox proportional-hazards regression was performed to assess whether the association between baseline PSA and PCSM was comparable for all age groups. A Lorenz curve was computed to assess the association between baseline PSA and PCSM for men aged 60–61 yr. Results and limitations: The overall actuarial probability at 16 yr ranged from 12% to 16% for any PCa and from 3.7% to 5.7% for csPCa across the age groups. The actuarial probability of csPCa at 16 yr ranged from 1.2–1.5% for men with PSA &lt;1.0 ng/ml to 13.3–13.8% for men with PSA ≥3.0 ng/ml. The association between baseline PSA and PCSM differed marginally among the three age groups. A Lorenz curve for men aged 60–61 yr showed that 92% of lethal PCa cases occurred among those with PSA above the median (1.21 ng/ml). In addition, for men initially screened at age 60–61 yr with baseline PSA &lt;2 ng/ml, further continuation of screening is unlikely to be beneficial after the age of 68–70 yr if PSA is still &lt;2 ng/ml. No case of PCSM emerged in the subsequent 8 yr (up to age 76–78 yr). A limitation is that these results may not be generalizable to an opportunistic screening setting or to contemporary clinical practice. Conclusions: In all age groups, baseline PSA can guide decisions on the repeat screening interval. Baseline PSA of &lt;1.0 ng/ml for men aged 55–69 yr is a strong indicator to delay or stop further screening. Patient summary: In prostate cancer screening, the patient's baseline PSA (prostate-specific antigen) level can be used to guide decisions on when to repeat screening. The PSA test when used according to current knowledge is valuable in helping to reduce the burden of prostate cancer.</p

IODP Expedition 334: An Investigation of the Sedimentary Record, Fluid Flow and State of Stress on Top of the Seismogenic Zone of an Erosive Subduction Margin

The Costa Rica Seismogenesis Project (CRISP) is an experiment to understand the processes that control nucleation and seismic rupture of large earthquakes at erosional subduction zones. Integrated Ocean Drililng Program (IODP) Expedition 334 by R/V JOIDES Resolution is the first step toward deep drilling through the aseismic and seismic plate boundary at the Costa Rica subduction zone offshore the Osa Peninsula where the Cocos Ridge is subducting beneath the Caribbean plate. Drilling operations included logging while drilling (LWD) at two slope sites (Sites U1378 and U1379) and coring at three slope sites (Sites U1378–1380) and at one site on the Cocos plate (Site U1381). For the first time the lithology, stratigraphy, and age of the slope and incoming sediments as well as the petrology of the subducting Cocos Ridge have been characterized at this margin. The slope sites recorded a high sediment accumulation rate of 160–1035m m.y.-1 possibly caused by on-land uplift triggered by the subduction of the Cocos Ridge. The geochemical data as well as the in situ temperature data obtained at the slope sites suggest that fluids are transported from greater depths. The geochemical profiles at Site U1381 reflect diffusional communication of a fluid with seawater-like chemistry and the igneous basement of the Cocos plate (Solomon et al., 2011; Vannucchi et al., 2012a). The present-day in situ stress orientation determined by borehole breakouts at Site U1378 in the middle slope and Site U1379 in the upper slope shows a marked change in stress state within ~12 km along the CRISP transect; that may correspond to a change from compression (middle slope) to extension (upper slope)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France

<p>Abstract</p> <p>Background</p> <p>We have previously shown that a panel of kallikrein markers - total prostate-specific antigen (PSA), free PSA, intact PSA and human kallikrein-related peptidase 2 (hK2) - can predict the outcome of prostate biopsy in men with elevated PSA. Here we investigate the properties of our panel in men subject to clinical work-up before biopsy.</p> <p>Methods</p> <p>We applied a previously published predictive model based on the kallikrein panel to 262 men undergoing prostate biopsy following an elevated PSA (≥ 3 ng/ml) and further clinical work-up during the European Randomized Study of Prostate Cancer screening, France. The predictive accuracy of the model was compared to a "base" model of PSA, age and digital rectal exam (DRE).</p> <p>Results</p> <p>83 (32%) men had prostate cancer on biopsy of whom 45 (54%) had high grade disease (Gleason score 7 or higher). Our model had significantly higher accuracy than the base model in predicting cancer (area-under-the-curve [AUC] improved from 0.63 to 0.78) or high-grade cancer (AUC increased from 0.77 to 0.87). Using a decision rule to biopsy those with a 20% or higher risk of cancer from the model would reduce the number of biopsies by nearly half. For every 1000 men with elevated PSA and clinical indication for biopsy, the model would recommend against biopsy in 61 men with cancer, the majority (≈80%) of whom would have low stage <it>and </it>low grade disease at diagnosis.</p> <p>Conclusions</p> <p>In this independent validation study, the model was highly predictive of prostate cancer in men for whom the decision to biopsy is based on both elevated PSA and clinical work-up. Use of this model would reduce a large number of biopsies while missing few cancers.</p

Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure

Active surveillance (AS) is broadly described as a management option for men with low-risk prostate cancer, but semantic heterogeneity exists in both the literature and in guidelines. To address this issue, a panel of leading prostate cancer specialists in the field of AS participated in a consensus-forming project using a modified Delphi method to reach international consensus on definitions of terms related to this management option. An iterative three-round sequence of online questionnaires designed to address 61 individual items was completed by each panel member. Consensus was considered to be reached if >= 70% of the experts agreed on a definition. To facilitate a common understanding among all experts involved and resolve potential ambiguities, a face-to-face consensus meeting was held between Delphi survey rounds two and three. Convenience sampling was used to construct the panel of experts. In total, 12 experts from Australia, France, Finland, Italy, the Netherlands, Japan, the UK, Canada and the USA participated. By the end of the Delphi process, formal consensus was achieved for 100% (n = 61) of the terms and a glossary was then developed. Agreement between international experts has been reached on relevant terms and subsequent definitions regarding AS for patients with localized prostate cancer. This standard terminology could support multidisciplinary communication, reduce the extent of variations in clinical practice and optimize clinical decision making.Peer reviewe